Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

NCT05617963 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer

NCT04905316 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

NCT04255836 ·Status: UNKNOWN ·Phase: PHASE2

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

NCT03519971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

NCT01595074 ·Status: NOT_YET_RECRUITING

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

NCT03822351 ·Status: COMPLETED ·Phase: PHASE2

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

NCT03585998 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

NCT03963414 ·Status: TERMINATED ·Phase: PHASE1

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

NCT04449861 ·Status: COMPLETED ·Phase: PHASE3

Durvalumab as Consolidation for Patients LS-SCLC

NCT07055581 ·Status: RECRUITING ·Phase: PHASE2

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

NCT03999710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial

NCT04432142 ·Status: ACTIVE_NOT_RECRUITING

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

NCT03141359 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NCT04716946 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

NCT04870112 ·Status: TERMINATED ·Phase: PHASE1

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy

NCT05267392 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

NCT05034133 ·Status: UNKNOWN ·Phase: PHASE2

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

NCT03353675 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 ·Status: RECRUITING ·Phase: PHASE3

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer

NCT02075957 ·Status: UNKNOWN

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

NCT05941897 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT03693300 ·Status: COMPLETED ·Phase: PHASE2

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NCT03164772 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study

NCT04897386 ·Status: UNKNOWN ·Phase: PHASE2